Equities

Zyversa Therapeutics Inc

ZVSA:NAQ

Zyversa Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)2.20
  • Today's Change-0.07 / -3.08%
  • Shares traded41.44k
  • 1 Year change-95.25%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments3.145.900.33
Total Receivables, Net------
Total Inventory------
Prepaid expenses0.220.230.11
Other current assets, total--0.240.38
Total current assets3.356.360.81
Property, plant & equipment, net0.010.120.03
Goodwill, net0120
Intangibles, net191000
Long term investments------
Note receivable - long term------
Other long term assets0.100.050.29
Total assets221191.13
LIABILITIES
Accounts payable8.436.032.00
Accrued expenses1.762.061.91
Notes payable/short-term debt009.15
Current portion long-term debt/capital leases------
Other current liabilities, total--0.110.56
Total current liabilities108.1914
Total long term debt000
Total debt009.15
Deferred income tax0.84100
Minority interest------
Other liabilities, total------
Total liabilities111914
SHAREHOLDERS EQUITY
Common stock0.000.330.33
Additional paid-in capital11410540
Retained earnings (accumulated deficit)(103)(4.92)(53)
Treasury stock - common(0.01)----
Unrealized gain (loss)------
Other equity, total------
Total equity11100(13)
Total liabilities & shareholders' equity221191.13
Total common shares outstanding0.410.030.03
Treasury shares - common primary issue0.0000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.